AIDS and its dementia as a neuropeptide disorder: Role of VIP receptor blockade by human immunodeficiency virus envelope
- 1 January 1988
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 23 (S1) , S71-S73
- https://doi.org/10.1002/ana.410230719
Abstract
The CD4 molecule was originally described as a marker for a subset of lymphocytes; however, recent work has shown that a similar, if not identical, molecule is present on human brain. We have realized that this cell-surface recognition molecule is normally modulated by vasoactive intestinal peptide (VIP), one of the 50 or more neuropeptides that compose a shared intercellular network joining the brain, glands, and immune system. Human immunodeficiency virus (HIV), the etiological agent of acquired immunodeficiency syndrome (AIDS), has been found to mimic VIP binding via peptide T (4–8), a pentapeptide sequence present in approximately the same region of all 20 HIV isolates whose sequences are currently known. AIDS dementia results from interference of gp120, present on the HIV envelope protein, with normal VIP-ergic neurotrophic effects, and effects on cerebral blood flow.Keywords
This publication has 5 references indexed in Scilit:
- CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxisFEBS Letters, 1987
- Autoradiographic Localization of T4 Antigen, the HIV Receptor, in Human BrainInternational Journal of Neuroscience, 1987
- Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity.Proceedings of the National Academy of Sciences, 1986
- Vasoactive intestinal peptide and electrical activity influence neuronal survival.Proceedings of the National Academy of Sciences, 1986
- Neuropeptides and their receptors: a psychosomatic networkThe Journal of Immunology, 1985